Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 382

1.

Is DBCG abreast of new developments?

Offersen BV, Ejlertsen B, Balslev E, Flyger H, Gerdes AM, Hansen MK, Hølmich LR, Jensen MB, Kristensen B, Laenkholm AV, Mouridsen HT, Nielsen MH, Overgaard J, Tuxen M, Vejborg I, Christiansen P.

Acta Oncol. 2018 Jan;57(1):1-2. doi: 10.1080/0284186X.2017.1408960. Epub 2018 Jan 3. No abstract available.

PMID:
29297250
2.

Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.

Ejlertsen B, Offersen BV, Overgaard J, Christiansen P, Jensen MB, Kroman N, Knoop AS, Mouridsen H.

Acta Oncol. 2018 Jan;57(1):3-12. doi: 10.1080/0284186X.2017.1408962. Epub 2017 Dec 5.

PMID:
29205077
3.

The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.

Jensen MB, Laenkholm AV, Offersen BV, Christiansen P, Kroman N, Mouridsen HT, Ejlertsen B.

Acta Oncol. 2018 Jan;57(1):13-18. doi: 10.1080/0284186X.2017.1404638. Epub 2017 Dec 5.

PMID:
29202621
4.

Provision of data from the clinical database and of biological material from the tumor bank of the Danish Breast Cancer Cooperative Group 2008-2017.

Mouridsen H, Christiansen P, Jensen MB, Laenkholm AV, Flyger H, Offersen B, Vejborg I, Ejlertsen B.

Acta Oncol. 2018 Jan;57(1):154-156. doi: 10.1080/0284186X.2017.1403039. Epub 2017 Dec 5. No abstract available.

PMID:
29202619
5.

The occurrence of fractures after adjuvant treatment of breast cancer: a DBCG register study.

Kristensen B, Ejlertsen B, Jensen MB, Mouridsen HT; Danish Breast Cancer Cooperative Group.

Acta Oncol. 2018 Jan;57(1):141-145. doi: 10.1080/0284186X.2017.1403043. Epub 2017 Nov 23.

PMID:
29168668
6.

Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial.

Jensen MB, Krarup JF, Palshof T, Mouridsen HT, Ejlertsen B.

Acta Oncol. 2018 Jan;57(1):26-30. doi: 10.1080/0284186X.2017.1400179. Epub 2017 Nov 22.

PMID:
29165021
7.

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group.

Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.

8.

Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT.

J Clin Oncol. 2017 Aug 10;35(23):2639-2646. doi: 10.1200/JCO.2017.72.3494. Epub 2017 Jun 29.

PMID:
28661759
9.

Danish Breast Cancer Cooperative Group.

Christiansen P, Ejlertsen B, Jensen MB, Mouridsen H.

Clin Epidemiol. 2016 Oct 25;8:445-449. eCollection 2016. Review.

10.

Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment.

Jensen MB, Ejlertsen B, Mouridsen HT, Christiansen P; Danish Breast Cancer Cooperative Group.

Acta Oncol. 2016 Jun;55 Suppl 2:24-35. doi: 10.3109/0284186X.2015.1128119. Epub 2016 Jan 21.

PMID:
26797010
11.

Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.

Ejlertsen B, Jensen MB, Mouridsen HT; Danish Breast Cancer Cooperative Group.

Acta Oncol. 2014 Feb;53(2):174-85. doi: 10.3109/0284186X.2013.850738. Epub 2013 Nov 13.

PMID:
24219541
12.

One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.

Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT.

Eur J Cancer. 2013 Sep;49(14):2986-94. doi: 10.1016/j.ejca.2013.05.006. Epub 2013 Jun 8.

PMID:
23756360
13.

[Danish Breast Cancer Cooperative Group].

Mouridsen HT, Møller S, Christiansen P.

Ugeskr Laeger. 2012 Oct 15;174(42):2532. Danish. No abstract available.

PMID:
23079435
14.

Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.

Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT.

J Clin Oncol. 2012 Nov 10;30(32):3967-75. doi: 10.1200/JCO.2011.40.8666. Epub 2012 Oct 8.

15.

Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.

Nielsen KV, Ejlertsen B, Møller S, Jensen MB, Balslev E, Müller S, Knoop A, Mouridsen HT.

Mol Oncol. 2012 Feb;6(1):88-97. doi: 10.1016/j.molonc.2011.11.006. Epub 2011 Nov 26.

16.

Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.

Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H; Danish Breast Cancer Cooperative Group; BIG 1-98 Collaborative Group; International Breast Cancer Study Group.

Ann Oncol. 2012 May;23(5):1138-44. doi: 10.1093/annonc/mdr438. Epub 2011 Oct 10.

17.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

18.

Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark.

Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Lænkholm AV, Kroman N, Ewertz M, Offersen B, Toftdahl DB, Møller S, Mouridsen HT; Danish Breast Cancer Cooperative Group.

J Natl Cancer Inst. 2011 Sep 21;103(18):1363-72. doi: 10.1093/jnci/djr299. Epub 2011 Aug 31.

PMID:
21881042
19.

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2011 Oct;22(10):2201-7. doi: 10.1093/annonc/mdq738. Epub 2011 Feb 18.

20.

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A.

J Clin Oncol. 2011 Mar 20;29(9):1117-24. doi: 10.1200/JCO.2010.31.6455. Epub 2011 Feb 14.

21.

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.

Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO, Jakobsen E, Møller S, Lindman H, Blomqvist C.

Acta Oncol. 2011 Apr;50(3):329-37. doi: 10.3109/0284186X.2011.554435. Epub 2011 Feb 8.

PMID:
21299448
22.

Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.

Mouridsen HT, Lønning P, Beckmann MW, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M.

Expert Rev Anticancer Ther. 2010 Nov;10(11):1825-36. doi: 10.1586/era.10.160. Epub 2010 Sep 30. Review.

PMID:
20883112
23.

The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.

Mouridsen HT.

Cancer Invest. 2010;28 Suppl 1:1-3. doi: 10.3109/07357907.2010.501632. No abstract available.

PMID:
20653402
24.

Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.

Nielsen KV, Ejlertsen B, Müller S, Møller S, Rasmussen BB, Balslev E, Lænkholm AV, Christiansen P, Mouridsen HT.

Breast Cancer Res Treat. 2011 Jun;127(2):345-55. doi: 10.1007/s10549-010-0984-y. Epub 2010 Jun 17.

PMID:
20556506
25.

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.

Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B.

Breast Cancer Res Treat. 2010 Aug;123(1):163-9. doi: 10.1007/s10549-010-0931-y. Epub 2010 May 13.

26.

Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.

Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS; Danish Breast Cancer Cooperative Group.

Cancer. 2010 May 1;116(9):2081-9. doi: 10.1002/cncr.24969.

27.

HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.

Ejlertsen B, Jensen MB, Nielsen KV, Balslev E, Rasmussen BB, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brünner N.

J Clin Oncol. 2010 Feb 20;28(6):984-90. doi: 10.1200/JCO.2009.24.1166. Epub 2009 Dec 28.

PMID:
20038724
28.

The risk of amenorrhoea after adjuvant chemotherapy for early stage breast cancer is related to inter-individual variations in chemotherapy-induced leukocyte nadir in young patients: data from the randomised SBG 2000-1 study.

Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre K, Andersson M.

Eur J Cancer. 2009 Dec;45(18):3198-204. doi: 10.1016/j.ejca.2009.09.019. Epub 2009 Oct 7.

PMID:
19818599
29.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

30.

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.

Klintman M, Ørnbjerg Würtz S, Christensen IJ, Braemer Hertel P, Fernö M, Malmberg M, Mouridsen H, Cold F, Schrohl AS, Foekens JA, Malmström P, Brünner N.

Breast Cancer Res Treat. 2010 Jun;121(2):365-71. doi: 10.1007/s10549-009-0483-1. Epub 2009 Aug 4.

PMID:
19653096
31.

Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.

Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brünner N.

Eur J Cancer. 2009 Sep;45(14):2528-36. doi: 10.1016/j.ejca.2009.05.029. Epub 2009 Jun 15.

PMID:
19535243
32.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

33.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

34.

Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer.

Ejlertsen B, Jensen MB, Rank F, Rasmussen BB, Christiansen P, Kroman N, Kvistgaard ME, Overgaard M, Toftdahl DB, Mouridsen HT; Danish Breast Cancer Cooperative Group.

J Natl Cancer Inst. 2009 May 20;101(10):729-35. doi: 10.1093/jnci/djp090. Epub 2009 May 12.

PMID:
19436035
35.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
36.

Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients.

Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brünner N, Nauntofte B.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Aug;106(2):217-26. doi: 10.1016/j.tripleo.2008.04.003. Epub 2008 Jun 13.

PMID:
18554960
37.

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group.

Nielsen OS, Dombernowsky P, Mouridsen H, Daugaard S, Van Glabbeke M, Kirkpatrick A, Verweij J.

Sarcoma. 2000;4(1-2):31-5. doi: 10.1155/S1357714X00000062.

38.

Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.

Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P, Ewertz M, Kamby C, Lindman H, Nordenskjöld B, Bergh J.

Acta Oncol. 2008;47(4):740-6. doi: 10.1080/02841860801964988.

PMID:
18465343
39.

Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group.

Langkjer ST, Ejlertsen B, Mouridsen H, Andersen J, Nielsen MM, Møller KA, Madsen EL, Haarh V; Danish Breast Cancer Co-operative Group.

Acta Oncol. 2008;47(4):735-9. doi: 10.1080/02841860801971421.

PMID:
18465342
40.

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.

Nielsen KV, Ejlertsen B, Møller S, Jørgensen JT, Knoop A, Knudsen H, Mouridsen HT.

Acta Oncol. 2008;47(4):725-34. doi: 10.1080/02841860801995396.

PMID:
18465341
41.

DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients.

Ejlertsen B, Jensen MB, Mouridsen HT, Andersen J, Cold S, Jakobsen E, Kamby C, Sørensen PG, Ewertz M.

Acta Oncol. 2008;47(4):709-17. doi: 10.1080/02841860802001475.

PMID:
18465339
42.

Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol.

Blichert-Toft M, Nielsen M, Düring M, Møller S, Rank F, Overgaard M, Mouridsen HT.

Acta Oncol. 2008;47(4):672-81. doi: 10.1080/02841860801971439.

PMID:
18465335
43.
44.
45.

TIMP-1 as a tumor marker in breast cancer--an update.

Würtz SO, Schrohl AS, Mouridsen H, Brünner N.

Acta Oncol. 2008;47(4):580-90. doi: 10.1080/02841860802022976. Review.

PMID:
18465326
46.

Improvement of prognosis in breast cancer in Denmark 1977-2006, based on the nationwide reporting to the DBCG Registry.

Mouridsen HT, Bjerre KD, Christiansen P, Jensen MB, Møller S.

Acta Oncol. 2008;47(4):525-36. doi: 10.1080/02841860802027009.

PMID:
18465318
47.

The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.

Møller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT; Danish Breast Cancer Cooperative Group.

Acta Oncol. 2008;47(4):506-24. doi: 10.1080/02841860802059259.

PMID:
18465317
48.

Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.

Blichert-Toft M, Christiansen P, Mouridsen HT.

Acta Oncol. 2008;47(4):497-505. doi: 10.1080/02841860802068615.

PMID:
18465316
49.

Inappropriate ATAC on tamoxifen.

Coates A, Mouridsen H, Thürlimann B; BIG 1-98 Collaborative Group.

Lancet Oncol. 2008 Apr;9(4):315-6. doi: 10.1016/S1470-2045(08)70085-8. No abstract available.

PMID:
18374287
50.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A.

J Clin Oncol. 2008 Apr 20;26(12):1972-9. doi: 10.1200/JCO.2007.14.0459. Epub 2008 Mar 10.

PMID:
18332471

Supplemental Content

Loading ...
Support Center